Dr. Reddy’s Laboratories shares: The pharma major posted a sharp 86% YoY drop in Q4FY26 consolidated net profit to Rs 221 crore, compared with Rs 1,587 crore a year ago. Following the weak earnings performance, several brokerages cut their target prices on the stock.
Recent Posts
- Silver price hits 6% upper circuit to ₹2.95 lk as India hikes import duty amid West Asia tensions, sticky US inflation
- SBI share price crashes 10% in 2 days after Q4 results – Should investors buy the dip or stay cautious?
- Bullion bears brace for pain as duty hike to lock gold, silver at upper circuits on MCX
- Don’t buy gold for 1 year? These Nifty500 stocks outperformed bullion
- Buy or sell: Gift Nifty signals muted start, Vaishali Parekh recommends three intraday stocks for today — 13 May 2026